Was the Gilead Sciences (GILD) CFO’s share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Such plans pre-schedule trades, indicating this sale was pre-arranged rather than timed at the executive’s discretion.

Gilead Sciences (NASDAQ: GILD) CFO sells 3,000 shares under 10b5-1 plan

Q: What insider transaction did Gilead Sciences (GILD) report for its CFO?

Gilead Sciences’ CFO Andrew D. Dickinson reported selling 3,000 shares of common stock. The shares were sold in an open-market transaction at $140.96 per share , as disclosed in a Form 4 insider trading report.

Q: At what price did the Gilead Sciences (GILD) CFO sell his shares?

The Gilead Sciences CFO sold 3,000 shares of common stock at $140.96 per share . This was an open-market sale reported on Form 4 and executed under a pre-arranged Rule 10b5-1 trading plan .

Q: What type of transaction did the Gilead Sciences (GILD) CFO execute?

The CFO executed an open-market sale of Gilead Sciences common stock. The Form 4 identifies the transaction code as “S” , meaning a sale in the open market or a private transaction, covering 3,000 shares at $140.96 each.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported an open-market sale of company stock. On this Form 4, he sold 3,000 shares of Gilead Sciences common stock at a price of $140.96 per share.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating it was scheduled in advance. Following this sale, Dickinson continues to hold 176,191 shares of Gilead Sciences common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares ($422,880)

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 3,000 shs ($423K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$140.96	$423K

Holdings After Transaction: Common Stock — 176,191 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 3,000 shares Sale price per share: $140.96 per share Shares held after transaction: 176,191 shares

3 metrics

Shares sold 3,000 shares Open-market sale of Gilead Sciences common stock

Sale price per share $140.96 per share Price received in the April 15, 2026 transaction

Shares held after transaction 176,191 shares Direct holdings of CFO Andrew D. Dickinson following the sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/16/2026 - 06:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last)

(First)

(Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/15/2026		S⁽¹⁾		3,000	D	$140.96	176,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Gilead Sciences (GILD) report for its CFO?

Gilead Sciences’ CFO Andrew D. Dickinson reported selling 3,000 shares of common stock. The shares were sold in an open-market transaction at $140.96 per share, as disclosed in a Form 4 insider trading report.

At what price did the Gilead Sciences (GILD) CFO sell his shares?

The Gilead Sciences CFO sold 3,000 shares of common stock at $140.96 per share. This was an open-market sale reported on Form 4 and executed under a pre-arranged Rule 10b5-1 trading plan.

How many Gilead Sciences (GILD) shares does the CFO hold after this sale?

After selling 3,000 shares, the Gilead Sciences CFO directly holds 176,191 shares of common stock. This post-transaction holding is disclosed in the Form 4 and reflects his remaining direct ownership position in Gilead Sciences.

What type of transaction did the Gilead Sciences (GILD) CFO execute?

The CFO executed an open-market sale of Gilead Sciences common stock. The Form 4 identifies the transaction code as “S”, meaning a sale in the open market or a private transaction, covering 3,000 shares at $140.96 each.